whatshot

RARE   $58.29  -0.83% Market Open

Ultragenyx Pharmaceutical Inc
show_chart Advanced Chart of RARE
Last Events:

2023-08-09 Trend Power changed from almost flat to slow.

2023-08-05 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.

2023-08-05 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-04 Trend pattern changed from нисходящий клин to сужающийся канал.

2023-08-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-30 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-07-30 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

Current temperature: 13.18
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 20
Target Price Mean 89.80
Mean unverified/preliminary 89.80 / 89.80
Target Price Low / High 46.00 / 140.00
Median / STD DEV 79.00 / 27.77
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy None
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 None Sell Sell
ma50 Sell None None
ma100 Sell Buy Buy
Candlestick PatternSept. 17, 2024 Deliberation Block Formation - consists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.
ISIN US90400D1081
ceo Dr. Emil D. Kakkis M.D., Ph.D.
Website https://www.ultragenyx.com
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.